Reports
Sale
Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market: By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Others; By Drugs: Over-the-Counter Drugs, Prescription; By Route of Administration: Oral, Parenteral; By Distribution Channels: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size
The global non-steroidal anti-inflammatory drugs (NSAIDs) market attained a value of USD 21.70 billion in 2023, driven by a shift from opioid analgesics use of NSAIDs and enhancing client’s knowledge of their side effects across the globe. The market is further expected to grow at a CAGR of 5.40% between 2024 and 2032 to reach a value of USD 34.84 billion by 2032.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Outlook
- The market value is expected to grow with a preference for NSAIDs for mild to moderate pain treatment and avoid opioid dependence.
- Rising incidence of arthritis, muscle pain, premenstrual menstrual cramps, and injuries like sprains are likely to augment the market demand for NSAIDs in the forecast period.
- The market is witnessing more investments intended to improve access to NSAIDs. Such efforts are expected to boost the market value in coming years.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to alleviate pain, inflammation, and fever. Chronic pain being a long-term problem, that worsens health and economic issues due to reduced productivity and higher health costs. NSAIDs work by reducing prostaglandins (compounds that involved in causing pain and inflammation). These drugs help manage pain from arthritis, muscle pain, headache, premenstrual menstrual cramps, and injuries like sprains and strains. They are available without over the counter as common pain relievers like ibuprofen (Advil, Motrin) and naproxen (Aleve), and by prescription. Most NSAIDs are taken orally, but some are available as creams and gels for direct application to the skin to relieve localized pain.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Drivers
Increasing Utilization of NSAIDs to Treat Multiple Conditions
With strong research and development investments, the global market for NSAIDs is set to grow in the forecast period. This growth is impacted by rising incidence of diseases that cause pain and inflammation. Bone and joint-related issues like rheumatoid arthritis and osteoarthritis comprise a major share wherein NSAIDs are used. In addition, surge in surgical procedures in hospitals is leading increased adoption of NSAIDs. Pain disorders and the aging population prone to various diseases are also increasing the need for the drugs. Additionally, rising support for pain management from end-users, helped by government and healthcare policies, ensures market expansion.
Increased Preference Over Opioids to Boost the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Demand
Despite the widespread use of opioids for pain relief, there is a growing trend towards prescribing NSAIDs due to the harmful effects of opioids. This has led to a push for safer pain management options. The American Academy of Family Physicians advises over-the-counter drugs like ibuprofen and naproxen as the primary treatment for mild to moderate pain. Such recommendations are likely to further boost the NSAIDs market value in the forecast period.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends
| Key Trends | Impact |
| Changes in Drug Formulation to Boost Efficacy | Both healthcare professionals and consumers are increasingly concerned about the long-term side effects of NSAID medication and therapy. This has led to better measures to balance risk and boost its efficacy to provide improved patient outcomes. |
| Rising Sports-Related Injuries | As more people engage in sports and exercise, the rate of sport-related injuries has increased. Doctors often prescribe topical NSAIDs for these injuries because they effectively treat localized pain and inflammation. Therefore, the use of topical NSAIDs is rapidly growing in sports medicine and physical therapy. |
| Investments to Provide Effective Healthcare Facilities | Improving healthcare facilities and related infrastructures are major market trends boosting market growth. More business associations and joint ventures are focusing on funding and adoption modern technologies, with both public and private organizations leading the way. |
| Over-the-counter (OTC) Availability and Convenience | Common NSAIDs are available over the counter (OTC), making them accessible without a prescription. This easy access leads consumers to seek quick relief from pain. Forms like gels, creams, and patches allow individuals to use NSAIDs easily without needing a doctor's consultation. |
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation
Market Breakup by Disease Indication
- Arthritis
- Migraine
- Ophthalmic Diseases
- Others
Market Breakup by Drugs
- Over-the-Counter Drugs
- Aspirin
- Ibuprofen
- Naproxen
- Celecoxib
- Others
- Prescription
- Daypro
- Indocin
- Lodine
- Naprosyn
- Relafen
- Vimovo
- Voltaren
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Share
Arthritis Stands as the Most Dominant Category for the Forecast Period
The market segmentation based on disease indications is divided into arthritis, migraine, ophthalmic diseases, and others. Arthritis, including osteoarthritis and rheumatoid arthritis, is estimated to lead the market share in the forecast period. With chronic pain and inflammation as a common symptom, NSAID prescriptions are commonly referred by medical professionals. Ibuprofen-based products are especially popular because they work well and are easy to get. The rising prevalence of arthritis, especially in an aging population, significantly influences the NSAIDs market. NSAIDs also treat headaches and eye disorders, further boosting market growth. Ongoing research aims to meet the diverse needs of patients and healthcare providers.
Ibuprofen is Leading the Market Share Based on Drug Types
The market segmentation by drugs encompasses various drugs, which include over-the-counter drugs (Aspirin, Ibuprofen, Naproxen, Naproxen, Celecoxib, Others) and prescription (Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, Voltaren). Ibuprofen, an OTC medication, leads the market, due to its effectiveness in treating pain and inflammation. Its various formulations cater to different patient needs. Despite this, ibuprofen is preferred over aspirin for its wider usage across different ages and therapies. Research, policy changes, and new competitors may impact the market by either reducing ibuprofen’s market share or providing opportunities for new competitors to emerge.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market by Region
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are all included in the regional market analysis. North America holds a substantial market share for NSAIDs because of the large population and common health issues such as arthritis and chronic pain present in this region. Developed nations ensure the availability of these drugs in healthcare facilities. Proper advertising informs customers about these products. Regulatory agencies such as the Food and Drug Administration in the USA and Health Canada inspect and verify NSAIDs' safety and efficacy before and after market approval.
In Asia Pacific region, many large companies manufacture and distribute NSAIDs, with strong research efforts to ensure quality and safety. Asia Pacific, with its large population and increasing arthritis cases, is expected to witness rapid growth in the forecast period. Government policies on treatment pricing and coverage, along with economic development in Southeast Asia and South Asia greatly influence demand.
Recent Developments in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
In March 2024, Endo International plc launched the first flu pill. It is called ibuprofen-famotidine 800 mg/26. They launched it through their subsidiaries Par Pharmaceutical, Inc. This new generic medication, DUEXIS®, treats rheumatoid arthritis and osteoarthritis. It also reduces the risk of ulcers in the stomach and upper intestine that come from ibuprofen. This innovation offers better treatment options for arthritis patients. It shows Endo International’s commitment to advancing drugs.
In May 2023, AbbVie got approval from the U. S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib). It's a new treatment for adults with moderately to severely active Crohn’s disease. This approval is expected to greatly impact the treatment of Crohn’s disease. It will give patients a new treatment choice and improve their quality of life. It is also likely to boost AbbVie’s revenues.
In January 2023, Sun Pharma acquired three brands from Aksigen Hospital Care, namely Disperzyme, Disperzyme-CD, and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg), and Rutoside Trihydrate 100 mg. This acquisition is strategic and aims to improve Sun Pharma’s anti-inflammatory medicine range. It will provide more treatment options for patients. Sun Pharma hopes to use these well-known brands and to expand its market in anti-inflammatory drugs.
Leading Players in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
The key features of the market report include patent analysis, and strategic initiatives such as partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:
Bayer AG
It is a Germany-based company that offers various NSAIDs including Aspirin (Bayer®, St. Joseph®). Ibuprofen (Motrin®, Advil®). Naproxen sodium (Aleve®)
Novartis AG
Established in 1996 and headquartered in Switzerland, the company is involved in the production of various medications, including NSAIDs. One notable NSAID produced by Novartis is Diclofenac.
Pfizer Inc.
The company was established in 1849 and has its base in New York. It deals with various NASID products like Celecoxib, and Ibuprofen.
Johnson & Johnson Private Limited
Based in the U.S., this company was founded in 1957. The company produces various NSAIDs which include Naproxen, Diclofenac,
Other companies in the market include Assertio Holdings, Inc., Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, and Sanofi India Limited.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Indication |
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report
- What was the global non-steroidal anti-inflammatory drugs (NSAIDs) market value in 2023?
- What is the global non-steroidal anti-inflammatory drugs (NSAIDs) market forecast outlook for 2024-2032?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- What is the market segmentation based on disease indication?
- What is the market breakup based on drugs?
- What is the market segmentation based on route of administration?
- What are major distribution channels in the market?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the global non-steroidal anti-inflammatory drugs (NSAIDs) market demand?
- Which country is expected to experience expedited growth during the forecast period?
- What are the implications of rising online pharmacy sales for the distribution of NSAIDs, and how do traditional pharmacies respond to this trend?
- What are the major global non-steroidal anti-inflammatory drugs (NSAIDs) market trends?
- How does the rise in the geriatric population impact the market size?
- What are the safety and efficacy concerns associated with long-term NSAID use, and how do they influence prescribing decisions?
- Who are the key players involved in the non-steroidal anti-inflammatory drugs (NSAIDs) market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the leading disease indications driving the non-steroidal anti-inflammatory drugs (NSAIDs) market demand?
- Which NSAID drugs dominate the over-the-counter segment, and what factors contribute to their popularity?
- What are the primary distribution channels through which NSAIDs are distributed to consumers, and how does each channel contribute to market penetration?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
3.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Historical Value (2017-2023)
3.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Landscape*
5.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Product Landscape
5.2.1 Analysis by Disease Indication
5.2.2 Analysis by Route of Administration
6 Global Infectious Diseases Epidemiology Snapshot
6.1 Global Infectious Disease Incidence Number Overview (2017 – 2032)
6.2 Global Infectious Disease Incidence – by Disease (2017 – 2032)
6.2.1 Arthritis
6.2.2 Migraine
6.2.3 Ophthalmic Diseases
7 Global Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Dynamics
7.1 Market Drivers and Constraints
7.2 SWOT Analysis
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats
7.3 PESTEL Analysis
7.3.1 Political
7.3.2 Economic
7.3.3 Social
7.3.4 Technological
7.3.5 Legal
7.3.6 Environment
7.4 Porter’s Five Forces Model
7.4.1 Bargaining Power of Suppliers
7.4.2 Bargaining Power of Buyers
7.4.3 Threat of New Entrants
7.4.4 Threat of Substitutes
7.4.5 Degree of Rivalry
7.5 Key Demand Indicators
7.6 Key Price Indicators
7.7 Industry Events, Initiatives, and Trends
7.8 Value Chain Analysis
8 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation (2017-2032)
8.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
8.1.1 Market Overview
8.1.2 Arthritis
8.1.3 Migraine
8.1.4 Ophthalmic Diseases
8.1.5 Others
8.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
8.2.1 Over-the-Counter Drugs
8.2.1.1 Aspirin
8.2.1.2 Ibuprofen
8.2.1.3 Naproxen
8.2.1.4 Naproxen
8.2.1.5 Celecoxib
8.2.1.6 Others
8.2.2 Prescription
8.2.2.1 Daypro
8.2.2.2 Indocin
8.2.2.3 Lodine
8.2.2.4 Naprosyn
8.2.2.5 Relafen
8.2.2.6 Vimovo
8.2.2.7 Voltaren
8.3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
8.3.1 Market Overview
8.3.2 Oral
8.3.3 Parenteral
8.4 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
8.4.1 Market Overview
8.4.2 Hospital Pharmacy
8.4.3 Retail Pharmacy
8.4.4 Online Pharmacy
8.4.5 Others
8.5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Region
8.5.1 Market Overview
8.5.2 North America
8.5.3 Europe
8.5.4 Asia Pacific
8.5.5 Latin America
8.5.6 Middle East and Africa
9 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
9.1 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
9.1.1 Market Overview
9.1.2 Arthritis
9.1.3 Migraine
9.1.4 Ophthalmic Diseases
9.1.5 Others
9.2 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
9.2.1 Over-the-Counter Drugs
9.2.1.1 Aspirin
9.2.1.2 Ibuprofen
9.2.1.3 Naproxen
9.2.1.4 Naproxen
9.2.1.5 Celecoxib
9.2.1.6 Others
9.2.2 Prescription
9.2.2.1 Daypro
9.2.2.2 Indocin
9.2.2.3 Lodine
9.2.2.4 Naprosyn
9.2.2.5 Relafen
9.2.2.6 Vimovo
9.2.2.7 Voltaren
9.3 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
9.3.1 Market Overview
9.3.2 Oral
9.3.3 Parenteral
9.4 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
9.4.1 Market Overview
9.4.2 Hospital Pharmacy
9.4.3 Retail Pharmacy
9.4.4 Online Pharmacy
9.4.5 Others
9.5 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
9.5.1 United States of America
9.5.2 Canada
10 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
10.1 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
10.1.1 Market Overview
10.1.2 Arthritis
10.1.3 Migraine
10.1.4 Ophthalmic Diseases
10.1.5 Others
10.2 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
10.2.1 Over-the-Counter Drugs
10.2.1.1 Aspirin
10.2.1.2 Ibuprofen
10.2.1.3 Naproxen
10.2.1.4 Celecoxib
10.2.1.5 Others
10.2.2 Prescription
10.2.2.1 Daypro
10.2.2.2 Indocin
10.2.2.3 Lodine
10.2.2.4 Naprosyn
10.2.2.5 Relafen
10.2.2.6 Vimovo
10.2.2.7 Voltaren
10.3 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
10.3.1 Market Overview
10.3.2 Oral
10.3.3 Parenteral
10.4 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
10.4.1 Market Overview
10.4.2 Hospital Pharmacy
10.4.3 Retail Pharmacy
10.4.4 Online Pharmacy
10.4.5 Others
10.5 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
10.5.1 United Kingdom
10.5.2 Germany
10.5.3 France
10.5.4 Italy
10.5.5 Others
11 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
11.1 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
11.1.1 Market Overview
11.1.2 Arthritis
11.1.3 Migraine
11.1.4 Ophthalmic Diseases
11.1.5 Others
11.2 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
11.2.1 Over-the-Counter Drugs
11.2.1.1 Aspirin
11.2.1.2 Ibuprofen
11.2.1.3 Naproxen
11.2.1.4 Naproxen
11.2.1.5 Celecoxib
11.2.1.6 Others
11.2.2 Prescription
11.2.2.1 Daypro
11.2.2.2 Indocin
11.2.2.3 Lodine
11.2.2.4 Naprosyn
11.2.2.5 Relafen
11.2.2.6 Vimovo
11.2.2.7 Voltaren
11.3 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.4.5 Others
11.5 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 ASEAN
11.5.5 Australia
11.5.6 Others
12 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
12.1 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
12.1.1 Market Overview
12.1.2 Arthritis
12.1.3 Migraine
12.1.4 Ophthalmic Diseases
12.1.5 Others
12.2 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
12.2.1 Over-the-Counter Drugs
12.2.1.1 Aspirin
12.2.1.2 Ibuprofen
12.2.1.3 Naproxen
12.2.1.4 Naproxen
12.2.1.5 Celecoxib
12.2.1.6 Others
12.2.2 Prescription
12.2.2.1 Daypro
12.2.2.2 Indocin
12.2.2.3 Lodine
12.2.2.4 Naprosyn
12.2.2.5 Relafen
12.2.2.6 Vimovo
12.2.2.7 Voltaren
12.3 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Parenteral
12.4 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
12.4.1 Market Overview
12.4.2 Hospital Pharmacy
12.4.3 Retail Pharmacy
12.4.4 Online Pharmacy
12.4.5 Others
12.5 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
12.5.1 Brazil
12.5.2 Argentina
12.5.3 Mexico
12.5.4 Others
13 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032)
13.1 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Disease Indication
13.1.1 Market Overview
13.1.2 Arthritis
13.1.3 Migraine
13.1.4 Ophthalmic Diseases
13.1.5 Others
13.2 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Drugs
13.2.1 Over-the-Counter Drugs
13.2.1.1 Aspirin
13.2.1.2 Ibuprofen
13.2.1.3 Naproxen
13.2.1.4 Naproxen
13.2.1.5 Celecoxib
13.2.1.6 Others
13.2.2 Prescription
13.2.2.1 Daypro
13.2.2.2 Indocin
13.2.2.3 Lodine
13.2.2.4 Naprosyn
13.2.2.5 Relafen
13.2.2.6 Vimovo
13.2.2.7 Voltaren
13.3 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Route of Administration
13.3.1 Market Overview
13.3.2 Oral
13.3.3 Parenteral
13.4 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Distribution Channels
13.4.1 Market Overview
13.4.2 Hospital Pharmacy
13.4.3 Retail Pharmacy
13.4.4 Online Pharmacy
13.4.5 Others
13.5 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2017-2032) by Country
13.5.1 Saudi Arabia
13.5.2 United Arab Emirates
13.5.3 Nigeria
13.5.4 South Africa
13.5.5 Others
14 Regulatory Framework
14.1 Regulatory Overview
14.2 US FDA
14.3 EU EMA
14.4 INDIA CDSCO
14.5 JAPAN PMDA
14.6 Others
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication Year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Strategic Initiative
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share Analysis, By Region (Top 5 Companies)
17.1.1 Market Share Analysis: Global
17.1.2 Market Share Analysis: North America
17.1.3 Market Share Analysis: Europe
17.1.4 Market Share Analysis: Asia-Pacific
17.1.5 Market Share Analysis: Others
17.2 Assertio Holdings, Inc .
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bayer AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Amgen Inc
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Lion Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Dr. Reddy’s Laboratories Ltd .
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc .
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Johnson & Johnson Private Limited
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 GlaxoSmithKline plc
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sanofi India Limited
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER